Authors:
G Attard, J Clark, L Ambroisine, IG Mills, G Fisher, P Flohr, A Reid, S Edwards, G Kovacs, D Berney, C Foster, CE Massie, A Fletcher, JS De Bono, P Scardino, J Cuzick, CS Cooper, Transatlantic Prostate Group
Journal name: 
Br J Cancer
Citation info: 
99(2):314-320
Abstract: 
A fluorescence in situ hybridisation (FISH) assay has been used to screen for ETV1 gene rearrangements in a cohort of 429 prostate cancers from patients who had been diagnosed by trans-urethral resection of the prostate. The presence of ETV1 gene alterations (found in 23 cases, 5.4%) was correlated with higher Gleason Score (P=0.001), PSA level at diagnosis (P=<0.0001) and clinical stage (P=0.017) but was not linked to poorer survival. We found that the six previously characterised translocation partners of ETV1 only accounted for 34% of ETV1 re-arrangements (eight out of 23) in this series, with fusion to the androgen-repressed gene C15orf21 representing the commonest event (four out of 23). In 5'-RACE experiments on RNA extracted from formalin-fixed tissue we identified the androgen-upregulated gene ACSL3 as a new 5'-translocation partner of ETV1. These studies report a novel fusion partner for ETV1 and highlight the considerable heterogeneity of ETV1 gene rearrangements in human prostate cancer.
DOI: 
http://doi.org/10.1038/sj.bjc.6604472
E-pub date: 
22 Jul 2008